Europe’s CBD business is rising from the novel meals period smaller, weaker and stripped of most of the firms that fueled the sector’s early increase.
What started as a regulatory train has was a possible business washout, already eliminating a big share of the market’s early contributors. A whole bunch of firms that when rushed into the sector through the CBD increase are actually gone, dormant or stripped all the way down to survival mode because the economics behind ingestible “wellness” CBD proceed to deteriorate.
In the UK alone, practically 500 firms have been at one time related to roughly 12,000 merchandise on the Meals Requirements Company’s (FSA) CBD novel meals record. Some analysts estimate that roughly half of these firms have since disappeared.
Intense stress
The lengthy delays tied to the UK’s FSA course of compounded the stress. Firms have been compelled to maintain working in limbo whereas ready years for scientific evaluations and toxicology assessments that stay unresolved for a lot of the sector. By the point the FSA course of took form, the European CBD sector was already weakening after a boom-and-bust cycle that left an oversupply, resulting in falling costs.
The UK market was initially held collectively, partially, by consortium-style purposes to the FSA that mixed a whole bunch of manufacturers underneath shared toxicology and scientific information packages. One of the crucial outstanding was the UK’s Affiliation for the Cannabinoid Business (ACI) consortium, which included firms resembling British Hashish, Charlotte’s Net and Dragonfly Biosciences.
THIS SERIES:
• PART 1: UK’s swap to EU meals security guidelines might push 1000’s of CBD merchandise to lifeless finish
• PART 2: Europe’s CBD bottleneck tightens as UK pathway stalls earlier than EU regulatory handover
• PART 3: Europe’s CBD casualties mount as novel meals course of radically reshapes the market
• PART 4: What’s left: It stays to be seen if there’ll be a marketplace for CBD past medical formulation
However that grouping step by step light because the novel meals course of dragged on and prices escalated. Lots of the smaller manufacturers that entered underneath shared purposes disappeared, withdrew merchandise or fell into monetary misery.
Brokedown mannequin
In the meantime, the EU, by means of the European Meals Security Authority (EFSA), tightened security expectations and paused assessments over unresolved toxicology questions, narrowing the business pathway for ingestible CBD.
For smaller manufacturers, the unique promise of CBD as a low-barrier wellness class has largely evaporated. Many entered the market by means of white-label merchandise and contract manufacturing preparations through the late-2010s CBD surge, when private-label tinctures, capsules and edibles flooded Europe with few significant obstacles to entry.
That mannequin broke down as costs weakened, inventories piled up, and the regulatory scene shifted.
World challenges
The shakeout can also be being strengthened by broader international situations.
The CBD market seems to be sliding right into a second glut because the upheaval in Europe and a crackdown on CBD-based intoxicating hemp merchandise in the US collide with persistent oversupply from China.
Proof continues to mount that offer outpaces demand, significantly for CBD isolate. Reviews of unsold inventories, falling costs and stalled transactions recommend a market nonetheless struggling to soak up extra manufacturing.
Who’s out
The turmoil has already led to quite a few outstanding CBD firms and types disappearing from the FSA course of within the UK:
Charlotte’s Net/Savage Cabbage: The FSA’s November 2025 replace eliminated greater than 30 merchandise linked to joint Charlotte’s Net/Savage Cabbage purposes from the general public CBD record. It’s unclear whether or not the removals have been voluntary withdrawals, FSA-initiated actions, or a mix of each. Savage Cabbage had an extra 22 merchandise entered by itself, all of which have been additionally eliminated.
Publicly traded Charlotte’s Net, primarily based in Colorado, is among the many most outstanding CBD producers within the U.S. The corporate, which seems to not have reported the UK withdrawal in any official communication with shareholders, has struggled for years amid the broader collapse of the CBD sector, reporting persistent losses regardless of repeated restructuring efforts. The corporate misplaced roughly $30 million in 2025 whereas revenues remained flat at about $50 million.
Savage Cabbage is a UK-based CBD distributor and white-label operator that served as Charlotte’s Net’s official UK/EU associate through the novel meals course of. The corporate stays formally energetic within the UK, however Firms Home — the UK authorities’s company registry — exhibits a proposal to strike off the corporate, which means it might be dissolved and faraway from the register, whereas court docket filings tied to its father or mother, Cannim Group, described the enterprise as “borderline bancrupt.”
JM Wholesale of the UK misplaced greater than 300 of roughly 700 merchandise in evaluate as the results of a significant FSA purge early within the course of in January 2023. JM Wholesale is a distributor and wholesaler of CBD, vape and smoking merchandise that provides retailers throughout the UK by means of white-label, distribution and drop-shipping operations. The corporate bumped into monetary bother in 2026 amid tighter UK vape guidelines, and Firms Home now lists JM Wholesale as underneath insolvency safety.
British Hashish, one of many UK’s largest CBD operators, had about 50 merchandise faraway from its authentic submission of roughly 1,500 merchandise into the method. The corporate is a white-label provider, producing oils, capsules and different cannabinoid wellness merchandise underneath manufacturers resembling Canabidol and ACCESS CBD. The corporate additionally operates within the UK medical hashish sector.
RX Pharmatech, which exhibits roughly 1,300 merchandise nonetheless within the evaluate, had solely 10 of its merchandise eliminated, however the firm itself seems to have largely disappeared following the collapse and breakup of father or mother twenty second Century Group’s hemp and cannabinoid division. The U.S. tobacco and biotech firm acquired RX Pharmatech in 2023 by means of its hemp subsidiary, GVB Biopharma, whose toxicology and technical information underpinned most of the firm’s UK novel meals purposes. Later that yr, after heavy losses and a strategic retreat from hemp, twenty second Century offered off GVB, RX Pharmatech and associated belongings to a newly fashioned entity tied to former GVB insiders, leaving the long-term standing of the RX portfolio unclear.
Jersey Hemp had solely seven CBD merchandise within the FSA’s evaluate, however the firm’s profile was raised when it gained a landmark 2024 authorized case in opposition to the UK Dwelling Workplace, which had banned the import of its merchandise attributable to hint quantities of THC. Jersey Hemp stated shedding entry to the UK market on account of the lawsuit compelled it to put off workers and promote gear, and it has not regained any presence.
